All Truvada articles
-
NewsGilead data lends insight into transforming HIV prevention landscape
Results suggest that the small molecule treatment could be an alternative to current medication that aims to prevent HIV infection and which require more frequent dosing.
-
NewsGilead small molecule demonstrates strong capability for HIV prevention
According to Gilead, the study is the first Phase III HIV prevention trial to demonstrate a zero-infection rate.
-
ArticleUnlocking innovative hydrogel treatments
Researchers from Queen's University Belfast, Garry Laverty, Sreekanth Pentlavalli and Yuming An, delve into the potential of an innovative ‘hydrogel’ version of the HIV drug zidovudine.